Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer.

Cancer research and treatment - 1 Jan 2017

Kim Dalyong, Hong Yong Sang, Kim Jeong Eun, Kim Kyu-Pyo, Lee Jae-Lyun, Chun Sung-Min, Kim Jihun, Jang Se Jin, Kim Tae Won

Abstract excerpt

PURPOSE: Cetuximab demonstrates improved efficacy outcomes in patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS exon 2. Resistance to cetuximab is mediated by activating less frequent mutations in the RAS genes beyond KRAS exon 2. We performed extended RAS Mutational analysis using a high-throughput genotyping platform (OncoMap) and evaluated extended RAS analysis for predicting cetuximab...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Kaplan-Meier Estimate

Share to Neoplasm Grading

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins p21(ras)

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 27121720
DOI: 10.4143/crt.2016.069
PMCID: PMC5266405

Genes

KRAS
BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer.PMID 27121720Read ↗

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.Semantic proximity Read ↗

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.Semantic proximity Read ↗

Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT DatabaseSemantic proximity Read ↗

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.Semantic proximity Read ↗

RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.Semantic proximity Read ↗

RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data.Semantic proximity Read ↗

Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study.Semantic proximity Read ↗

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.Semantic proximity Read ↗

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial.Semantic proximity Read ↗

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.Semantic proximity Read ↗

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.